Friday, July 31, 2026

Classys Global Customer Summit 2026: Insights from 500 Medical Professionals Across 20 Countries

Classys successfully hosted its Global Customer Summit 2026, showcasing innovative medical devices and attracting over 500 professionals globally.

THE PUPPET’S CRUSH: Why the Blue House is Blushing Over a Mocking Message from Pyongyang

North Korea's Kim Yo-jong responds to a drone incident, expressing hope for improved inter-Korean relations after President Lee's regret.

Urinary Incontinence: More Than Just a Sign of Aging

Urinary incontinence affects many, worsened in winter; it’s treatable through various methods, emphasizing the importance of seeking help.

Tag: CDMO

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Samsung Biologics Accelerates “Three-Pillar Expansion Strategy” With Peptide CDMO Acquisition to Drive Global Growth

Samsung Biologics acquires Polypeptide Group for $1.8 billion, expanding into the peptide CDMO market to enhance growth and capabilities.

Interview: Huons’ PanGen Bets on ‘Development-Focused CDMO’ Strategy Built on Biosimilar Experience

South Korea's PanGen CDMO emphasizes development expertise and tailored services, enhancing drug development support for clients.

Lotte Biologics’ ‘Three Production Batches, 14% Utilization’ Underscores Need for New Orders Over New Plants

Lotte Biologics aims to enter the global CDMO market by expanding production, but faces challenges in securing contracts and profitability.

Lotte Biologics says it has secured top-10 global CDMO manufacturing capacity [BIO USA]

Lotte Biologics is set to begin commercial production by the end of 2026, advancing its capabilities in the global CDMO market.

Is BTGEN the Next Big Player in Biopharmaceuticals? Discover Their Unique CDMO Strategy

BTGEN is expanding its CDMO business with National Growth Fund support, focusing on innovative processes instead of competing on scale.

ST Pharm Targets Next-Generation RNA Therapies, Positions Itself as Key CDMO Partner at BIO USA

The RNA therapeutics market is evolving, with ST Pharm aiming to lead in precision manufacturing and targeted delivery for next-gen therapies.

Matica Bio Launches Open Access Platform: A Game Changer for Gene Therapy in 2026

Matica Bio launches an open CDMO platform for gene therapy, enhancing client control and streamlining production with Cirsium Biosciences.

Boryung Begins First Global CDMO Supply of Alimta Through Taiwan Partnership

Boryung Pharmaceutical starts supplying Alimta to Lotus, enhancing global CDMO efforts and addressing chemotherapy drug shortages.

ST Pharm Expands Global CDMO Outreach at TIDES USA and ASGCT 2026

ST Pharm showcased its CDMO capabilities at TIDES USA and ASGCT 2026, focusing on nucleic acid therapeutics and strategic partnerships.

Samsung Biologics Strengthens Global Partnerships at Decat Week 2026: Key Insights and Strategies

Samsung Biologics aims to enhance global partnerships at J.P. Morgan's Healthcare Conference 2026, showcasing its CDMO strengths.

HLB Pep Signs Deal with Japan’s ReproCELL to Supply Customized Neoantigen Peptides — The Future of Precision Medicine?

HLB PEP partners with Reprocell to supply customized neo-antigen peptides for personalized cancer treatment, targeting global markets.

Estipam Secures Record 897 Billion KRW Contract for Oligonucleotide Raw Materials: What This Means for the Asian Market

ST Pharm secures a record 89.7 billion KRW contract for oligonucleotide ingredients, enhancing its global market position.

Lotte Biologics at DCAT Week 2026: Unveiling Strategic Collaborations in Global CDMO

Lotte Biologics will attend DCAT Week in New York to pursue global CDMO partnerships and showcase its production capabilities.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.